What is claimed is:

1. Use of a nerve regenerating or nerve degeneration attenuating amount of phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide in the manufacture of a medicament for treating spinal cord injury comprising regenerating nerve or attenuating degeneration of nerve at a site of nerve injury wherein the medicament is to be administered at or an area near an injured nerve, wherein the PTEN inhibitor peptide is modified PTEN peptide or fragment thereof in which phosphorylation site is modified such that a serine in the phosphorylation site is phosphorylated.

2. The use according to claim 1, wherein the phosphorylated serine is located at position Ser-380 and Ser-385.

3. The use according to claim 1, wherein the phosphorylated serine is located at position Ser-380, Ser-385 and Ser-370.

4. The use according to claim 1, wherein the phosphorylated serine is located at position Ser-380, Ser-385 and/or Ser-370.

5. The use according to claim 1, wherein the peptide comprises an amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.

6. The use according to claims 1 to 5, wherein the peptide is a fragment of a peptide of phosphorylation site and/or PDZ domain binding motif.

7. The use according to claims 1 to 6, wherein the peptide further comprises a peptide transfer domain (PTD).

8. The use according to claims 1 to 7, wherein the nerve injury is in the central nervous system.

9. Use of a nerve regenerating or nerve degeneration attenuating amount of phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide in the manufacture of a medicament for treating a condition associated with or caused by spinal cord injury comprising regenerating nerve or attenuating degeneration of nerve at a site of nerve injury wherein the medicament is to be administered at or an area near an injured nerve, wherein the PTEN inhibitor peptide is modified PTEN peptide or fragment thereof in which phosphorylation site is modified such that a serine in the phosphorylation site is phosphorylated.

10. The use of claim 9, wherein the condition is neurogenic bladder.

11. The use of claims 9 and 10, wherein the condition is loss motor function.

12. The use of claims 9 to 11, wherein the condition is loss of movement coordination.